![]() | |
Clinical data | |
---|---|
Trade names | Marquis |
AHFS/Drugs.com | FDA Professional Drug Information |
Routes of administration | Oral |
ATCvet code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
ECHA InfoCard | 100.157.907 |
Chemical and physical data | |
Formula | C18H14F3N3O6S |
Molar mass | 457.38 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Ponazuril (INN), sold by Merial, Inc.,[1] now part of Boehringer Ingelheim,[2] under the trade name Marquis® (15% w/w ponazuril), is a drug currently approved for the treatment of equine protozoal myeloencephalitis (EPM) in horses, caused by coccidia Sarcocystis neurona.[3][4] Veterinarians have been preparing a formulary version of the medication for use in small animals such as cats, dogs, and rabbits against coccidia as an intestinal parasite. Coccidia treatment in small animals is far shorter than treatment for EPM.[citation needed]
See also
References
- ^ "Merial Acquires LEGEND® and MARQUIS®". Boehringer Ingelheim. Retrieved 2018-04-30.
- ^ "Sanofi and Boehringer Ingelheim confirm Closing of business swap | www.boehringer-ingelheim.com". boehringer-ingelheim.com. Retrieved 2018-04-30.
- ^ "Marquis". Drugs.com.
- ^ Mackay RJ, Tanhauser ST, Gillis KD, Mayhew IG, Kennedy TJ (March 2008). "Effect of intermittent oral administration of ponazuril on experimental Sarcocystis neurona infection of horses". American Journal of Veterinary Research. 69 (3): 396–402. doi:10.2460/ajvr.69.3.396. PMID 18312139.